75 related articles for article (PubMed ID: 7871286)
21. Phase I treatment of women with metastatic breast cancer with baboon anti-gross cystic disease fluid protein.
Estabrook A; Kister SJ; Hardy MA; Grossbard L; Oster MW; Davis S; Mazoujian G; Haagenson DE
Curr Surg; 1984; 41(5):375-8. PubMed ID: 6488876
[No Abstract] [Full Text] [Related]
22. Alpha-lactalbumin and GCDFP-15 as breast tumor markers (an opportunity to study breast tumors functionally).
Collette J; Van Cauwenberge JR; Le Doussal V; Serilas M; Hustin J; Carlisi A; Dejardin L; Franchimont P
Int J Rad Appl Instrum B; 1987; 14(4):385-95. PubMed ID: 3654256
[No Abstract] [Full Text] [Related]
23. [Symposium: New markers in hormone-dependent cancers].
Ann Endocrinol (Paris); 1985; 46(4-5):325-41. PubMed ID: 3837633
[No Abstract] [Full Text] [Related]
24. The apocrine carcinoma of the breast. A cytological, immunohistochemical and ultrastructural study of 6 cases.
Alexiev B; Boschnakova Z; Prokopanov C
Zentralbl Pathol; 1994 Jul; 140(2):129-34. PubMed ID: 7524651
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody B72.3 immunostaining of breast carcinoma. Patterns of staining and relationship to mucin content and GCDFP-15 reactivity.
Soomro S; Shousha S
Arch Pathol Lab Med; 1992 Jan; 116(1):32-5. PubMed ID: 1370877
[TBL] [Abstract][Full Text] [Related]
26. Osteoclastic giant cell tumor of the pancreas: an immunohistochemical study.
Dizon MA; Multhaupt HA; Paskin DL; Warhol MJ
Arch Pathol Lab Med; 1996 Mar; 120(3):306-9. PubMed ID: 8629913
[TBL] [Abstract][Full Text] [Related]
27. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
[No Abstract] [Full Text] [Related]
28. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer.
Simard J; Dauvois S; Haagensen DE; Lévesque C; Mérand Y; Labrie F
Endocrinology; 1990 Jun; 126(6):3223-31. PubMed ID: 2351114
[TBL] [Abstract][Full Text] [Related]
29. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.
Wallace ML; Longacre TA; Smoller BR
Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328
[TBL] [Abstract][Full Text] [Related]
30. Mammary origin of metastases. Immunohistochemical determination.
Chaubert P; Hurlimann J
Arch Pathol Lab Med; 1992 Nov; 116(11):1181-8. PubMed ID: 1444749
[TBL] [Abstract][Full Text] [Related]
31. Salivary duct carcinoma in the submandibular region.
Toyoda H; Yamaguchi K; Miura K; Fukuda H; Hashimoto K
Int J Oral Maxillofac Surg; 2003 Aug; 32(4):427-9. PubMed ID: 14505630
[TBL] [Abstract][Full Text] [Related]
32. [Serum markers in breast cancer and colorectal cancer (1997)].
Bellet D; Mlika-Cabanne N; Bedenne L; Brun B; Demeaux JL; Legrand JL; Lorimier G; Mignotte H; Ollivier JM; Piperno-Neumann S; Rinaldi Y; Rousset H; Rymer JC; Laversin S
Gynecol Obstet Fertil; 2001 Jan; 29(1):62-3. PubMed ID: 11217195
[No Abstract] [Full Text] [Related]
33. [Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma].
Thomas CM; Wobbes T; Bonfrer JM; Peterse JL; Nap M; Beex LV
Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2354-7. PubMed ID: 8264818
[No Abstract] [Full Text] [Related]
34. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
35. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
36. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma].
Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C
Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086
[TBL] [Abstract][Full Text] [Related]
37. Biological actions of prolactin in human breast cancer.
Shiu RP; Murphy LC; Tsuyuki D; Myal Y; Lee-Wing M; Iwasiow B
Recent Prog Horm Res; 1987; 43():277-303. PubMed ID: 3306837
[No Abstract] [Full Text] [Related]
38. Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization of extramammary Paget's disease.
Battles OE; Page DL; Johnson JE
Am J Clin Pathol; 1997 Jul; 108(1):6-12. PubMed ID: 9208972
[TBL] [Abstract][Full Text] [Related]
39. The immunopathology of gross cystic disease fluid proteins.
Mazoujian G; Haagensen DE
Ann N Y Acad Sci; 1990; 586():188-97. PubMed ID: 2357000
[No Abstract] [Full Text] [Related]
40. Serological tumor markers for monitoring breast cancer.
Sölétormos G
Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
